



Canadian Children Inflammatory Bowel Disease Network

A PARTNERSHIP WITH THE CH.I.L.D FOUNDATION

---

## July 2023 Newsletter

---


### News & Reminders

- The CIDSCaNN shared documents [Dropbox](#) has logo files and branded powerpoint templates for member use.
- We encourage CIDSCaNN members and trainees to develop research protocols, abstracts and publications using information from the [CIDSCaNN database](#).
- Did you know? Conference travel funds are available for trainees and early-stage investigators who submit and present abstracts of CIDSCaNN data. Find the application form [on the website](#).

---

## Current Projects

---

[Subscribe](#)[Past Issues](#)[Translate](#) ▼

## Phase 2 CIDSCaNN: AMBITION-CD

Assessment of Mucosal Biochemical and clinical response to Interleukin-12/23 or TNF Inhibitors in biologic-naïve Crohn's Disease

Inclusion criteria: Children age 2-17y with Crohn's disease starting first biologic as antiTNF or UST for luminal Crohn's disease

Participating sites: All

Target: 200 antiTNF, 100 UST

**AMBITION-CD Site Lead Meetings** take place the second Tuesday of each month.

We've now reached more than 100 participants in the AMBITION-CD analysis (114 as of this month). You can download the graphs from the website. We held a site leads meeting Tuesday June 13, and the next meeting will be September 12 at 3 p.m. EST.

Contact: Hayley [hayley.mckay@sickkids.ca](mailto:hayley.mckay@sickkids.ca)

Contact: Michelle [michelle.ouzounis@sickkids.ca](mailto:michelle.ouzounis@sickkids.ca)

[Subscribe](#)[Past Issues](#)[Translate ▾](#)

Biospecimen Type	Baseline (Date 0 or Anchor Date)
Biopsies	49 (41%)
DNA	73 (61%)
RNA	81 (68%)
Serum	84 (70%)
Stool	55 (46%)

Site	Enrolled in AMBITION-CD	Biologic	
		Ustekinumab	Anti TNF
Calgary	4	3	1
Ottawa	11	0	11
Montreal	1	1	1
Vancouver	8	0	8
Toronto	42	11	33
London	10	2	8
Edmonton	18	12	6
Halifax	5	2	3
St Johns	2	0	2
Winnipeg	12	2	10
Total	117	33	84

### Ongoing Follow-up of Inception Cohort Study

- Inclusion criteria: Children age 2-17y with IBD

### Dual biologics (via Main Prevalent Cohort Study)

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

- Contact: Wael [welmatary@exchange.hsc.mb.ca](mailto:welmatary@exchange.hsc.mb.ca)

### **Predictors of response to anti-TNF therapy (Biomark study)**

- Inclusion criteria: Children age 2-17y with luminal IBD starting first anti-TNF without prior surgery nor significant stenotic/penetrating disease requiring surgery in short-term
- Target: 75
- Participating sites: Toronto, Ottawa, Halifax
- Contact: Amanda [Amanda.ricciuto@sickkids.ca](mailto:Amanda.ricciuto@sickkids.ca)
- Contact: Shantel [Shantel.mangroo@sickkids.ca](mailto:Shantel.mangroo@sickkids.ca)

### **Implementing a Multimodal Intervention to Improve the Transition of Patients with Inflammatory Bowel Disease from Pediatric to Adult Care**

- Inclusion criteria: Aged 16-17.5 y with IBD, ability to provide informed consent, ability to speak/read English at a Grade 8 level, intention to reside in Canada after transfer to adult care, access to smartphone/computer (can be purchased for the participant if this is a barrier to participation)
- Target: 115
- Participating sites: Toronto, Ottawa, McMaster, BCCH
- Contact: Eric [eric.benchimol@sickkids.ca](mailto:eric.benchimol@sickkids.ca)

---

# Education Update

---

Most recent session:

**Session 7: Quality Improvement in IBD ([watch the recording here](#))**

Up-coming sessions:

September, 2023 — **Session 8: Topic and date to be determined**

November 14, 2023 — **Session 9: Transition from Pediatric to Adult Care in IBD: What Can CIDSCaNN Do To Improve Care?**

[Subscribe](#)[Past Issues](#)[Translate ▼](#)

future sessions. Thank you very much for your ongoing engagement and ideas!

Missed a past session? No problem! Listen to recordings at [cidscann.ca/education](https://cidscann.ca/education)

### Learn more & register

We encourage you to share the Education Session calendar invites with your multidisciplinary teams. Please find the dates for future sessions, and past recordings at [cidscann.ca/education](https://cidscann.ca/education)



---

## Publications, Awards & Grants

---

Congratulations to Dr. Eric Benchimol (Report Co-chair) and the Steering Committee and Working Group for the 2023 Impact of IBD in Canada report!

To read the report, visit [Crohn's and Colitis Canada website](#).

---

---

---

---

Subscribe

Past Issues

Translate ▾

# Thank you for your engagement & contribution to CIDSCaNN!

## PARTICIPATING SITES



Copyright © 2022 Canadian Children Inflammatory Bowel Disease Network, All rights reserved.

Our mailing address is:

555 University Avenue, Toronto ON Canada M5G 1X8

email: [info@cidscann.ca](mailto:info@cidscann.ca)

Want to change how you receive these emails?  
You can [update your preferences](#) or [unsubscribe from this list](#).

